Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.47 |
| ▸ | IKBKB | O14920 | 8/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655139 | 0.90 | EEF2K (0.36) | EEF2KIKBKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3088436 | 0.89 | EEF2K (0.53) | EEF2KIKBKBBRAFNPC1RAB9A | |
| SCHEMBL3087819 | 0.85 | EEF2K (0.55) | EEF2KIKBKBBRAFNPC1RAB9A | |
| SCHEMBL3092291 | 0.84 | EEF2K (0.56) | EEF2KIKBKBBRAFNPC1RAB9A | |
| SCHEMBL3083801 | 0.83 | EEF2K (0.55) | EEF2KIKBKBBRAFNPC1RAB9A | |
| SCHEMBL3089430 | 0.80 | EEF2K (0.51) | EEF2KIKBKBBRAFHSP90AB1KDM4E | |
| SCHEMBL14312330 | 0.78 | EEF2K (0.41) | EEF2KIKBKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3101766 | 0.76 | EEF2K (0.62) | EEF2KIKBKBBRAFSMN1; SMN2HSP90AB1 | |
| SCHEMBL3656598 | 0.74 | EEF2K (0.41) | EEF2KIKBKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3656993 | 0.73 | EEF2K (0.42) | EEF2KIKBKBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197886-B1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | TGFBR1, TGFBR2, ACVR1 | EEF2K 2875/4885IKBKB 599/4885BRAF 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.